Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera(®)). Efficacy and safety analysis. GeSida Study 8114

INTRODUCTION: Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients [1]. Switching to RPV may be convenient for many patients, while maintaining a good immunovirological control [2]. The aim of this study was to analyze lipid changes in HIV-patients at 24 weeks after sw...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Hernández, Isabel A, Palacios, Rosario, Mayorga, Marisa, González-Doménech, Carmen M, Castaño, Manuel, Rivero, Antonio, del Arco, Alfonso, Lozano, Fernando, Santos, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P263
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225353/
https://www.ncbi.nlm.nih.gov/pubmed/25397539
http://dx.doi.org/10.7448/IAS.17.4.19795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225353/
https://www.ncbi.nlm.nih.gov/pubmed/25397539
http://dx.doi.org/10.7448/IAS.17.4.19795

Ejemplares similares